

Announcement Summary

Entity name

ARGENT BIOPHARMA LIMITED

Announcement Type

New announcement

Date of this announcement

Wednesday April 23, 2025

The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

These securities have been issued to employees of the Company under an Employee Share Scheme. Approval to issue the securities was received on the same day on which the securities were issued, as such an appendix 3B was not deemed necessary as this Appendix 2A would be issued on the same day.

Total number of +securities to be quoted

| ASX +security code | Security description | Number of +securities to be quoted | Issue date |
|--------------------|----------------------|------------------------------------|------------|
| RGT | ORDINARY FULLY PAID | 500,000 | 23/04/2025 |

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

ARGENT BIOPHARMA LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

Registration number

ACN

116800269

1.3 ASX issuer code

RGT

1.4 The announcement is

New announcement

1.5 Date of this announcement

23/4/2025



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

These securities have been issued to employees of the Company under an Employee Share Scheme. Approval to issue the securities was received on the same day on which the securities were issued, as such an appendix 3B was not deemed necessary as this Appendix 2A would be issued on the same day.

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

RGT: ORDINARY FULLY PAID

Issue date

23/4/2025

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

500,000

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Nil, shares issues as part of employees working arrangements.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.180000

Any other information the entity wishes to provide about the +securities to be quoted

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

Shares issues as part of employees working arrangements.





Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

| ASX +security | code and | description | |
|---------------|----------|-------------|--|

Total number of +securities on issue

RGT : ORDINARY FULLY PAID 59,772,269

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|---------------------------------------------------------|-----------------------------------------|
| RGTAAO : WARRANTS EXPIRING 16-JAN-2028 EX USD 0.55 | 2,500,000 |
| RGTAAM : OPTION EXPIRING 28-MAR-2027 EX \$0.42 | 240,000 |
| RGTAAI : OPTION EXPIRING 31-JUL-2026 EX \$3.00 | 181,422 |
| RGTAAL : OPTION EXPIRING 10-JAN-2027 EX \$1.00 | 740,000 |
| RGTAAB : OPTION EXPIRING 01-APR-2029 EX \$0.70 | 131,000 |
| RGTAO : WARRANTS EXPIRING 17-JUL-2027 EX USD 1.20 | 1,250,000 |
| RGTAF : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 50,000 |
| RGTAAN : WARRANTS EXPIRING 03-JUL-2027 EX USD 1.20 | 312,500 |
| RGTAG : PERFORMANCE RIGHTS | 906,000 |
| RGTAAA : CONVERTIBLE NOTES | 6,306,432 |
| RGTAAJ : OPTION EXPIRING 07-NOV-2028 EX US\$0.32 | 15,500,000 |
| RGTAAH : OPTION EXPIRING 14-JUL-2026 EX GBP 1.2 | 540,668 |
| RGTAAE : CLASS D PERFORMANCE RIGHTS | 250 |
| RGTAAK : OPTION EXPIRING 01-DEC-2028 EX \$0.86 | 288,185 |





Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13